CVN417 is an orally active antagonist of nAChR containing the alpha6 subunit, modulating phasic dopaminergic neurotransmission in an impulse-dependent fashion. It inhibits Ca(2+) efflux through nAChR subunits, displaying IC50 values of 0.086 µM (alpha6), 2.56 µM (alpha3), and 0.657 µM (alpha4). CVN417 has shown efficacy in reducing resting tremor in rodent models, suggesting a potential to ameliorate movement disorders in conditions like Parkinsons disease [1].
Target:
AChR|||Others
* VAT and and shipping costs not included. Errors and price changes excepted
